The membrane-anchored MMP-regulator RECK is down regulated in many solid tumors; the extent of RECK down regulation correlates with poor prognosis. Forced expression of RECK in tumor cells results in suppression of angiogenesis, invasion, and metastasis. Studies on the roles and the mechanisms of regulation of the RECK gene during normal development may therefore yield important insights into how the malignant behaviors of tumor cells arise and how they can be controlled. Our previous studies indicate that mice lacking RECK die around E10.5 with reduced tissue integrity. In the present study, we have found that in later stage wild-type embryos, RECK is abundantly expressed in skeletal muscles, especially in the areas where the myoblast differentiation factor MRF4 is expressed. Consistent with this finding, the RECKpromoter is activated by MRF4 in cultured cells. In contrast, a myoblast determination factor MyoD suppresses the RECK-promoter. Myoblastic cells lacking RECK expression give rise to myotubes at higher efficiency than the cells expressing RECK, indicating that RECK suppresses myotube formation. These findings suggest that MyoD down regulates RECK to facilitate myotube formation, whereas MRF4 up regulates RECK to promote other aspects of myogenesis that require extracellular matrix integrity.
Introduction
Myogenesis is a multistep process involving determination, migration, alignment, and fusion of myoblasts to form myotubes that subsequently mature to give rise to muscle fibers (Buckingham et al., 2003) . These events are accompanied by the coordinated activation of muscle-specific genes many of which are regulated by a group of basic helix-loop-helix (bHLH) transcription factors termed myogenic regulatory factor (MRF) family consisting of four members: MyoD (Davis et al., 1987) , myogenin (Edmondson and Olson, 1989) , Myf5 (Braun et al., 1989) , and MRF4/Myf6/Herculin (Rhodes and Konieczny, 1989; Braun et al., 1990; Miner and Wold, 1990) . Although specific roles of each MRF family member during skeletal muscle development are yet to be fully understood, it is believed that the early expression of Myf5 in the epaxial dermomyotome and of MyoD and MRF4 in the hypaxial dermomyotome play important roles in trunk muscle determination (reviewed in (Buckingham et al., 2003; Chang et al., 2004; Fomin et al., 2004) ). In addition, MRF4 is believed to play important roles in later stages of muscle development, since the second wave expression of MRF4 persists even in adult muscles where most of the other MRF family members are down regulated (Buckingham et al., 2003; Chang et al., 2004; Fomin et al., 2004) . Despite these apparently distinct roles during myogenesis, MRFs share similar properties; they confer myogenic potential when expressed in fibroblastic cells, they bind to the similar recognition sequences termed E-box in the promoters of muscle-specific genes, and in some instances, they are functionally redundant (Kassar-Duchossoy et al., 2004) or even interchangeable (Zhu and Miller, 1997) in transgenic mice.
Several earlier reports have implicated extracellular matrix (ECM) and its regulatory enzymes such as matrix metalloproteinases (MMPs) in myoblast migration and fusion (Couch and Strittmatter, 1983; Chin and Werb, 1997; El Fahime et al., 2000; Osses and Brandan, 2002) . We previously found that mice lacking two members of the MMP family, MMP-2 and MT1-MMP, die immediately after birth with immature skeletal muscle fibers and abnormal blood vessels (Oh et al., 2004) . Other proteases, such as ADAM12 (meltrin-a) (YagamiHiromasa et al., 1995) and calpain (Schollmeyer, 2003) , as well as a number of other types of molecules have also been implicated in muscle cell differentiation and fusion (Chen and Olson, 2004; Horsley and Pavlath, 2004) . Although recent studies in Drosophila begin to shed lights on the molecular mechanisms of myoblast fusion (Chen and Olson, 2004) , exact roles of, and the relationship among, the ECM, proteases, and the other molecules in skeletal muscle development remain largely unclear at the moment.
RECK was first isolated as a transformation suppressor gene by expression cloning in a mouse fibroblast cell line transformed by an activated RAS oncogene (Takahashi et al., 1998) . While the RECK gene is widely expressed in various human organs, its expression is low or undetectable in tumor-derived cell lines; also, RECK expression can be down-regulated by several oncogenes including RAS (Sasahara et al., 1999) . RECK encodes a GPI-anchored glycoprotein that regulates at least three members of the MMP family, MMP-2, MMP-9, and MT1-MMP/MMP-14, in vitro or in cultured cells. Mice lacking functional RECK allele die around embryonic day 10.5 (E10.5) with smaller-than-normal body size and massive hemorrhage. Histological examination of these mutant embryos revealed severe disarray of mesenchymal tissues, deprivation of fibrillar collagen, and abnormal organogenesis, suggesting essential roles for RECK and regulated ECM remodeling in mammalian development earlier than this stage (Oh et al., 2001) . However, the roles for RECK in the later stages of development, including the skeletal muscle formation and maturation, remained to be elucidated.
Since some MMPs are essential for proper muscle development (Oh et al., 2004) and RECK regulates these MMPs (Takahashi et al., 1998; Oh et al., 2001) , we asked in this study whether RECK plays any roles in the regulation of skeletal muscle development. Our findings based on histochemical approach as well as experiments with myogenic cells in culture indicate that MyoD down regulates RECK to facilitate myotube formation, probably through relaxed MMP regulation, while MRF4 up regulates RECK to support other aspects of muscle development.
Results

Expression of RECK in developing muscles in mice
To find clues to the functions of RECK in post-E10.5 development in mice, we examined the distribution of RECK proteins in wild-type embryos at various stages by immunohistochemistry using anti-RECK antibodies. In E13.5 embryos (Figure 1a MyoD (Figure 1e ) but was similar to that of MRF4. For instance, RECK and MRF4 signals were more abundant in the areas near the ends of myofibrils ( Figure 1d and f, red arrowheads) and near cartilage ( Figure 1d and f, blue arrows), while the MyoD signals are more abundant near the central region of myofibrils ( Figure 1e , red bracket). In E14.5 embryos (Figure 1g) , strong RECK signals surrounding individual myofibrils were observed.
Effects of myogenic transcription factors on RECK promoter activity
We previously found that the RECK gene is regulated at the transcription level by the Ras signaling pathway (Sasahara et al., 1999) . We therefore tested whether the myogenic transcription factors such as MRFs may also regulate the RECK promoter ( Figure 2a ). A reporter plasmid containing the firefly luciferase gene under the control of the 4.1 kb RECK promoter fragment was cotransfected with complementary DNA encoding MyoD, myf-5, myogenin, or MRF4 into a murine fibroblast cell line, C3H10T1/2, known to be susceptible to MRF-induced myogenic differentiation. After 48 h incubation, cell extracts were prepared and the luciferase activity was measured. Interestingly, the RECK promoter was suppressed by MyoD, while it was activated by the other MRFs ( Figure 2a ). Similar results were obtained when the RECK promoter fragments of three different sizes, including the one that only contains the minimum promoter (À52-þ 82) (Sasahara et al., 1999) , were used ( Figure 2b ). The RECK minimum promoter contains three known cis-acting elements: a cEBPb site and two Sp1 sites (Sp1(A) and Sp1(B)). Suppressive effects of MyoD on this minimum promoter was abolished when Sp1(B) site was mutated (Figure 2c , solid bars), suggesting involvement of this site in the suppression. On the other hand, the activating effects of MRF4 on the RECK minimum promoter was enhanced when either Sp1(A) or Sp1(B) site was mutated ( Figure 2c , striped bars), suggesting negative effects of these elements on MRF4-mediated activation of RECK promoter.
Effects of MyoD on endogenous RECK
The above observations raised the possibility that MyoD-mediated down regulation of endogenous RECK at the transcription level might somehow contribute to the myogenic activity of MyoD. To confirm that the endogenous RECK gene and the protein are indeed regulated by MyoD expression, we introduced either a vacant retroviral vector (control) or the vector expressing MyoD into C3H10T1/2 cells and cultured these Luciferase activity relative to the vector control is shown. Note that MyoD represses RECK promoter (i.e., lower than 1) whereas other MRFs more or less activate the promoter (i.e., higher than 1). Only the data with one dosage of MRF expression vector (0.8 mg) are shown, but the effects were dose-dependent in all cases (data not shown). (b) Effects of MyoD and MRF4 on the activity of 5 0 -truncated RECK promoter. Note that the 52 bp proximal region (the 'minimum promoter') was sufficient for MyoD-mediated repression and MRF4-mediated activation. (c) Effects of MyoD and MRF4 on the activity of the RECK minimum promoterharboring mutation in one of the two Sp1 sites (Sp1(A) and SP1(B)) or the cEBPb site. Note that MyoD no longer repressed the promoter-harboring mutation in the Sp1(B) site, while MRF4 could activate all the mutant promoters cells in growth medium (GM) or differentiation medium (DM) for 4 days ( Figure 3A ). The cells expressing MyoD and being incubated in DM (panel d) gave rise to numerous myotubes as reported previously (Davis et al., 1987) . The level of RECK mRNA, as detected by RNA blot hybridization, was lower in the cells expressing MyoD than the control in both GM and DM ( Figure 3B, lanes 2 and 4) . Similar difference at the protein level was also detected by immunoblot assay ( Figure 3C) . Hence, the expression of endogenous RECK gene can be suppressed by MyoD, and this suppression does not require cell differentiation.
Effects of RECK and MMP-2/MT1-MMP on myoblast fusion
We next examined the effects of RECK expression on myogenesis using three experimental systems in tissue culture.
First, we tested the effects of RECK and its targets, MMP-2 and MT1-MMP, on myoblast fusion in a murine myogenic cell line C2C12. This cell line shows high efficiency of myoblast fusion in culture (Yaffe and Saxel, 1977; Blau et al., 1985) and expresses little endogenous RECK. We introduced MMP-2-and MT1-MMP-expression vector or RECK-expression vector into C2C12 cells and established pools of stable transfectants (Figure 4a ). After incubation in differentiation medium for 8 days, the cells were stained with Hoechst dye to visualize multi nucleated myotubes (Figure 4b ). Quantitative data indicate that when MMP-2 and MT1-MMP were overexpressed, although the number of myotubes was not significantly different (Figure 4c: bars 1 and 2) , the number of nuclei per myotube was significantly increased (Figure 4d : bars 1 and 2). In contrast, when RECK was overexpressed, both the number of myotubes and the number of nuclei per myotube were significantly reduced ( Figure 4c and  d: bars 1 and 3) .
Second, we cultured the cells from a whole E10.5 embryo on a collagen-coated dish. After 16 day incubation, the culture gave rise to clusters of stringlike structures interspersed among various other types of colonies. These string-like structures were proven to be myotubes by their multi nucleated morphology and electrophysiological properties (Oh et al., 2004) . Interestingly, RECK-deficient embryos reproducibly gave rise to more myotube clusters than wild-type embryos (Figure 4e , bars 1 and 2). Slight reduction in the average number of myotube clusters was noted in the case of embryonic cells lacking MMP-2 and MT1-MMP, although the difference was not statistically significant ( Figure 4e, bar 3) . Importantly, the cells from embryos lacking three genes, RECK, MMP-2, and MT1-MMP, yielded far fewer myotube clusters than RECK-deficient cells (Figure 4e , bars 4 and 2), suggesting requirement for these MMPs in the observed increase in myotube formation by the RECK-deficient embryonic cells.
Third, we tested the effects of RECK on MyoDinduced differentiation of mouse embryo fibroblasts (MEFs). MEFs derived from RECK-deficient embryos were infected with either vacant retroviral vector or the vector expressing the RECK gene. MyoD-overexpressing sublines were generated from these cells by using another retroviral vector (Figure 5a ). The resulting cells were incubated in the differentiation medium for 5 days, followed by Hoechst staining (Figure 5b ). Both the number of myotubes (Figure 5c ) and the number of nuclei per myotube ( Figure 5d ) were much lower in the RECK-reconstituted MEFs than the RECK-deficient (vector-infected) MEFs.
These findings in vitro indicate that MMP-2 and MT1-MMP promote myoblast fusion, and that RECK suppresses myoblast fusion, possibly by inhibiting these MMPs.
Discussion
RECK is abundantly expressed in developing muscles. On the other hand, RECK suppresses myotube formation in vitro. How could we reconcile these findings? Members of the MRF family show distinct spatiotemporal expression patterns, and yet they share similar binding sequence (E-box) and biological activities in vitro as well as in vivo. These previous findings let to the notion that MRFs may be functionally interchangeable as long as they are expressed with correct spatiotemporal expression patterns. Here we have shown, however, that MyoD suppresses RECK expression while other MRFs, especially MRF4, augments RECK expression (Figure 2a) , which supports the hypothesis that these MRFs regulate distinct, but partially overlapped, sets of target genes to exert their specific biological functions. Figure 5e shows a working hypothesis based on the present findings to explain how RECK could contribute to the progression of myogenesis. MyoD is known to function as a myogenic determination factor and is expressed in cells acquiring competence for myoblast fusion. It is appropriate that RECK, a suppressor of myotube formation, is down regulated in myogenic cells at this stage. On the other hand, MRF4 is known as a myogenic differentiation factor whose expression persists during later stages of muscle development where individual myofibers become surrounded by basement membrane, grow in mass, and acquire mechanical strength. All these events require the integrity as well as the regulated remodeling of ECM, and it is appropriate that RECK, a regulator of ECMdegrading enzymes (MMPs), is up regulated during RECK as a target of MRFs M Echizenya et al these processes. Of note, up regulation of another MMP-regulator, tissue inhibitor of metalloproteinase-1 (TIMP-1), after fusion of myogenic human masseter cells in vitro has also been reported (Lewis et al., 2000) . It is of particular interest that MRF4 and RECK are coexpressed near the ends of myofibrils at E14.5 (Figure 1 , panels f and d), where myotendinous junctions are being formed, since ample evidence suggest the importance of various ECM components in this process (Tidball, 1994; Birk and Mayne, 1997; Ferguson et al., 2003) . What would be the mechanism by which RECK suppresses myotube formation? Our experiments indicated that cultured whole embryonic cells failed to form myotubes efficiently in the absence of MMP-2, and MT1-MMP, even in the absence of RECK (Figure 4e , bars 3 and 4). This finding suggests that MMP-2 and MT1-MMP are the major MMPs that promote myotube formation in this system and that RECK suppresses myotube formation by regulating these enzymes. Previous studies indicated the importance of MMP-2, -7, -9, and MT1-MMP (Caron et al., 1999; El Fahime et al., 2000; Lewis et al., 2000) in myotube formation. These enzymes may serve to eliminate ECM and/or cell surface components that intercalate and thereby hinder the fusion between two membranes. Beside the fusion itself, the preceding steps such as migration and alignment of myoblasts may also be affected by these MMPs. Thus, the critical step(s) and target(s) that are regulated by RECK during myotube formation needs to be elucidated in future studies.
What would be the mechanism by which MyoD represses the RECK promoter? The minimal RECK promoter contain no E-box sequence. Instead, the luciferase data using mutant promoter imply that the Sp1(B) site, which is located down stream of the transcription start site, is involved in MyoD-mediated repression. Vinals et al. (1997) described MyoDmediated downregulation of Sp1 in myogenic cells. This may seem to explain our observation. Our observation that the Sp1(B)-mutant promoter was insensitive to MyoD, however, indicates that the MyoD-mediated RECK downregulation should be explained by active repression rather than reduced activation. Biesiada et al. (1999) reported the formation of multiprotein transcriptional complex containing Sp1 and myogenic bHLH proteins on human cardiac a-actin promoter. In contrast to the present case, however, the cardiac a-actin promoter contains both Sp1 site and E-box, and the transcriptional complex promotes, rather than suppresses, transcription. It would be interesting to test the possibility that MyoD-mediated suppression of RECK promoter involves formation of similar but nonproductive Sp1/MyoD complex in the absence of consensus E-box sequence. The mechanism by which MRF4 stimulates RECK promoter is presently unclear but should involve other cis-element(s) as judged from our luciferase data (Figure 2c ). This issue should also be addressed in future studies.
In conclusion, our findings indicate the importance of RECK during muscle development. We also propose that myogenic differentiation can be divided into two stages based on the pattern of RECK-expression: (1) the early stage where MyoD down regulates RECK and promotes myoblast fusion, and (2) the later stage where MRF4 up regulates RECK and promotes myofibril maturation. Further studies, for instance, using CREloxP-mediated conditional gene inactivation will allow us to test this hypothesis more rigorously in vivo.
Materials and methods
Histological analyses
Sections of paraformaldehyde-fixed, paraffin-embedded embryos were stained with mouse monoclonal anti-RECK antibodies (5B11D12; supplied by Amgen), mouse monoclonal anti-MyoD antibodies (5.8A, DAKO), or rabbit polyclonal anti-MRF4 antibodies (sc-301, Santa Cruz) and visualized using appropriate secondary antibodies and DAB (stains brown) followed by nuclear counterstaining with hematoxilin (stains purple). In the case of RECK and MyoD staining, Envision þ (DAKO) was used to suppress background signals.
Cell culture E10.5. embryos were broken into 20-30 pieces by mild pipetting in 2 ml PBS. The tissue pieces were collected by brief centrifugation, resuspended in 0.5 ml aMEM containing 40% fetal bovine serum (FBS) plus antibiotics, and plated onto a collagen-coated 35 mm dish. After overnight incubation, the cells were fed with 1.5 ml medium and the incubation was continued for several days until culture reached confluence. The cells were trypsinized, dispersed by mild pipetting (allowing preservation of residual cell clumps), plated at a 1 : 3 splitting ratio, and incubated for 3-4 days. MEFs were established by continued passaging of these cultures. MEFs were maintained in aMEM containing 10% FBS. After infection with retrovirus (see below), MEFs were maintained in aMEM supplemented with 30% FBS and C3H10T1/2 cells in DMEM supplemented with 30% FBS. C2C12 murine myoblast cells were maintained in DMEM containing 15% FBS. Cotransfection of C2C12 cells with the pcDNA3.1( þ )/ hygro vector (Invitrogen) containing mouse MMP-2 cDNA and/or the pCXN2 vector containing human MT1-MMP cDNA was performed by the standard calcium phosphate method, followed by selection with 400 mg/ml hygromycin-B plus 1 mg/ml G418. Myotube formation was induced by incubating the cells (5 Â 10 4 /35 mm-dish) in DMEM containing 1% horse serum. Extent of myotube formation was assessed by counting the nuclei in multinucleated cells (i.e., the cell containing five or more nuclei) after staining the nuclei with Hoechst-33432.
Retroviral gene transfer
To produce helper-free ecotropic retroviral vectors, EcoPack293 packaging host (Clontech) was used following the manufacturer's instruction. The retroviral vector plasmid, pBabe-puro, pBabe-MyoD (Novitch et al., 1996) , pLXSB, or pL(hRECK)SB, was transfected into the cells using CalPhos Mammalian Transfection Kit (Clontech). MEFs and C3H10T1/2 cells (ATCC) were infected with virus suspension in the presence of polybrene (final concentration 8 mg/ml). After infection, cells were grown under selective condition (8 mg/ml puromycin for pBabe-based viruses and 8 mg/ml blasticidin-S for pLXSB-based viruses). Cells infected with pBabe-based vector were maintained in aMEM (MEFs) or DMEM (C3H10T1/2) supplemented with 30% FBS.
Luciferase assay
Plasmid DNA was purified using QIAfilter plasmid midi kit (Qiagen). Cells were plated onto 12-well plates (2 Â 10 4 /well) and after 24 h incubation, transfected with mixture of four plasmids (0.2 mg luciferase reporter plasmid (pGL3-4110) (Sasahara et al., 1999) , 0.05 mg pRL-TK plasmid (Promega), and 0.8 mg pcDNA3.1-hygro containing cDNA for MyoD, Myf5, MRF4, or myogenin) using FuGENE6 (Roche). At 24 h after transfection, cultures were washed with PBS and refed with fresh medium. After additional 24 h, expression of reporter genes was analysed using Dual-Luciferase Reporter Assay System (Promega).
Western blot analysis
Cultured cells were lysed in 25 mM HEPES (pH 7.1), 150 mM NaCl, 1% NP-40, 0.25% deoxycholate, 10% glycerol, 10 mM MgCl 2 , 1 mM EDTA, 0.1 % sodium dodecylsulfate (SDS), and protease inhibiter cocktail (Nakalai). The cell lysates were cleared by centrifugation, and their protein concentration was determined. The sample (30 mg protein) was separated by SDS-polyacrylamide gel electrophoresis (10 % acrylamide), followed by immunoblot detection using monoclonal antibodies against RECK (5B11D12) or MyoD (DAKO, 5.8A). For visualization, the Enhanced Chemiluminescence kit (Amersham) was used with HRP-conjugated anti-mouse IgG-F(ab 0 )2 monoclonal antibody.
RNA blot hybridization
Total RNA was extracted with ISOGEN (Nippongene) and analysed by RNA blot hybridization using 32 P-labeled mouse RECK cDNA (Takahashi et al., 1998) as a probe.
